{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Doedens JR"],"funding":["NodThera","NCI NIH HHS"],"pagination":["1438-1456"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11091978"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(5)"],"pubmed_abstract":["Interleukin (IL)-1β is an apex proinflammatory cytokine produced in response to tissue injury and infection. The output of IL-1β from monocytes and macrophages is regulated not only by transcription and translation but also post-translationally. Release of the active cytokine requires activation of inflammasomes, which couple IL-1β post-translational proteolysis with pyroptosis. Among inflammasome platforms, NOD-like receptor pyrin domain-containing protein 3 (NLRP3) is implicated in the pathogenesis of numerous human disorders in which disease-specific danger-associated molecular patterns (DAMPS) are positioned to drive its activation. As a promising therapeutic target, numerous candidate NLRP3-targeting therapeutics have been described and demonstrated to provide benefits in the context "],"journal":["ACS pharmacology & translational science"],"pubmed_title":["Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1<i>H</i>-pyrazol-4-yl)({[(2<i>S</i>)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework."],"pmcid":["PMC11091978"],"funding_grant_id":["P30 CA015704"],"pubmed_authors":["Harrison D","Diamond C","Smolak P","Schooley K","Gabel CA","Billinton A","Doedens JR","Watt AP","Koller BH","Nguyen M","Wescott H"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1<i>H</i>-pyrazol-4-yl)({[(2<i>S</i>)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework.","description":"Interleukin (IL)-1β is an apex proinflammatory cytokine produced in response to tissue injury and infection. The output of IL-1β from monocytes and macrophages is regulated not only by transcription and translation but also post-translationally. Release of the active cytokine requires activation of inflammasomes, which couple IL-1β post-translational proteolysis with pyroptosis. Among inflammasome platforms, NOD-like receptor pyrin domain-containing protein 3 (NLRP3) is implicated in the pathogenesis of numerous human disorders in which disease-specific danger-associated molecular patterns (DAMPS) are positioned to drive its activation. As a promising therapeutic target, numerous candidate NLRP3-targeting therapeutics have been described and demonstrated to provide benefits in the context ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-02T06:42:46.12Z","creation":"2026-05-25T03:07:55.176Z"},"accession":"S-EPMC11091978","cross_references":{"pubmed":["38751618"],"doi":["10.1021/acsptsci.4c00061"]}}